Inventiva obtains AMF approval for its financing prospectus

On October 14, 2024, Inventiva, a French-American biopharmaceutical player, announced the approval by the Autorité des marchés financiers (AMF) of its prospectus No. 24-432. This document relates to the issuance of common shares and pre-funded share subscription warrants. This prospectus includes the universal registration document, an amendment annexed thereto, as well as a securities note and a summary. This information is available on the Company's and the AMF's websites.

Inventiva, listed on Euronext Paris and Nasdaq, focuses on innovative treatments for metabolic steatohepatitis (MASH) and other unmet diseases. This financing is crucial to continue the development of its promising drugs in these areas.